Sam Brusco, Associate Editor11.29.22
Treace Medical Concepts has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpeedPlate rapid compression implant system for fracture fixation, osteotomy fixation, and joint arthrodesis of the foot and ankle.
SpeedPlate is designed for rapid delivery of titanium compression implants as enabling fixation tech with the company’s new Micro-Lapiplasty instrumentation—which allows the Lapiplasty procedure to be performed through 2 cm incisions.
“We are pleased to announce 510(k) clearance of our SpeedPlate technology. SpeedPlate represents an exciting new fixation platform for Treace as we continue to invest in targeted R&D efforts aimed at making our Lapiplasty therapy less invasive, faster, and easier for surgeons to perform, reinforcing our mission to improve surgical outcomes for bunion patients and advance Lapiplasty as the standard of care,” John T. Treace, CEO, founder, and board member told the press. “As with any procedure involving smaller incisions and less tissue dissection, we believe our Micro-Lapiplasty/SpeedPlate offering may translate to even faster patient recovery with less pain and swelling.”
Trace aims to begin limited release of SpeedPlate implants with Micro-Lapiplasty instrumentation in the first half of 2023, with expanded launch in the second half of the year.
SpeedPlate is designed for rapid delivery of titanium compression implants as enabling fixation tech with the company’s new Micro-Lapiplasty instrumentation—which allows the Lapiplasty procedure to be performed through 2 cm incisions.
“We are pleased to announce 510(k) clearance of our SpeedPlate technology. SpeedPlate represents an exciting new fixation platform for Treace as we continue to invest in targeted R&D efforts aimed at making our Lapiplasty therapy less invasive, faster, and easier for surgeons to perform, reinforcing our mission to improve surgical outcomes for bunion patients and advance Lapiplasty as the standard of care,” John T. Treace, CEO, founder, and board member told the press. “As with any procedure involving smaller incisions and less tissue dissection, we believe our Micro-Lapiplasty/SpeedPlate offering may translate to even faster patient recovery with less pain and swelling.”
Trace aims to begin limited release of SpeedPlate implants with Micro-Lapiplasty instrumentation in the first half of 2023, with expanded launch in the second half of the year.